| |
| |
|
| Insider
Information: |
Milano Vincent |
| Relationship: |
Director |
| City: |
Exton |
| State: |
PA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
78,847 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$293,462 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
78,847 |
|
|
| Total
Value |
$293,462 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
4
|
|
Stock
price went up :
|
1
|
1
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
1.0
|
| Percentage
Gain/Loss : |
 14.6%
|
 -141.2%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Verticalnet Inc |
VERT |
Director |
2008-01-25 |
0 |
2005-01-20 |
0 |
Premium* |
|
|
Viropharma Inc |
VPHM |
President and CEO, Dir... |
2014-01-24 |
0 |
2005-12-13 |
0 |
Premium* |
|
|
Aceragen, Inc |
ACGN |
|
2023-08-10 |
8,987 |
2014-12-12 |
0 |
Premium* |
|
|
Vanda Pharmaceuticals Inc. |
VNDA |
Director |
2018-06-13 |
10,000 |
2017-06-15 |
0 |
Premium* |
|
|
Spark Therapeutics, Inc. |
ONCE |
Director |
2019-12-17 |
0 |
2018-05-31 |
0 |
Premium* |
|
|
Biocryst Pharmaceuticals Inc |
BCRX |
Director |
2024-02-29 |
51,997 |
2021-11-24 |
0 |
Premium* |
|
|
Aclaris Therapeutics, Inc. |
ACRS |
Director |
2023-06-02 |
7,863 |
2022-06-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2024-02-29 |
4 |
A |
$5.63 |
$5,624 |
D/D |
999 |
51,997 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2023-11-30 |
4 |
A |
$5.88 |
$5,621 |
D/D |
956 |
50,998 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2023-08-31 |
4 |
A |
$7.11 |
$5,624 |
D/D |
791 |
50,042 |
0 |
- |
|
| ACGN |
Aceragen, Inc |
|
– • – |
2023-08-10 |
4 |
S |
$0.53 |
$1,750 |
D/D |
(3,283) |
8,987 |
0 |
% |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
16,745 |
49,251 |
0 |
- |
|
| ACRS |
Aclaris Therapeutics, Inc... |
Director |
– • – |
2023-06-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,507 |
7,863 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2023-05-31 |
4 |
A |
$8.27 |
$5,624 |
D/D |
680 |
32,506 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2023-02-28 |
4 |
A |
$8.85 |
$5,620 |
D/D |
635 |
31,826 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2022-11-30 |
4 |
A |
$13.36 |
$5,625 |
D/D |
421 |
31,191 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2022-08-31 |
4 |
A |
$13.90 |
$5,616 |
D/D |
404 |
30,770 |
0 |
- |
|
| ACRS |
Aclaris Therapeutics, Inc... |
Director |
– • – |
2022-06-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,356 |
3,356 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
– • – |
2021-11-24 |
4 |
B |
$12.19 |
$91,425 |
D/D |
7,500 |
17,500 |
2.39 |
% |
|
| ACGN |
Aceragen, Inc |
President & CEO |
• • – |
2021-01-12 |
4 |
S |
$4.20 |
$13,474 |
D/D |
(3,210) |
208,611 |
0 |
% |
|
| ACGN |
Aceragen, Inc |
President & CEO |
• • – |
2021-01-05 |
4 |
S |
$3.91 |
$10,700 |
D/D |
(2,740) |
211,821 |
0 |
% |
|
| ACGN |
Aceragen, Inc |
President & CEO |
• • – |
2020-12-22 |
4 |
AS |
$4.32 |
$160,525 |
D/D |
(37,169) |
214,561 |
0 |
% |
|
| ACGN |
Aceragen, Inc |
President & CEO |
• • – |
2020-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
128,170 |
251,730 |
0 |
- |
|
| ACGN |
Aceragen, Inc |
President & CEO |
• • – |
2020-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
37,000 |
123,560 |
0 |
- |
|
| ACGN |
Aceragen, Inc |
President & CEO |
• • – |
2020-01-07 |
4/A |
AS |
$1.78 |
$5,352 |
D/D |
(3,006) |
86,560 |
0 |
- |
|
| ACGN |
Aceragen, Inc |
President & CEO |
• • – |
2020-01-07 |
4 |
S |
$1.78 |
$5,352 |
D/D |
(3,006) |
86,560 |
0 |
% |
|
| ONCE |
Spark Therapeutics, Inc. |
Director |
– • – |
2019-12-17 |
4 |
D |
$114.50 |
$343,500 |
D/D |
(3,000) |
0 |
0 |
- |
|
| ONCE |
Spark Therapeutics, Inc. |
Director |
– • – |
2019-05-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,500 |
3,000 |
0 |
- |
|
| ACGN |
Aceragen, Inc |
President & CEO |
• • – |
2019-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
33,750 |
89,566 |
0 |
- |
|
| ACGN |
Aceragen, Inc |
President & CEO |
• • – |
2018-12-24 |
4 |
B |
$2.93 |
$43,923 |
D/D |
15,000 |
55,816 |
2.81 |
- |
|
| ACGN |
Aceragen, Inc |
President & CEO |
• • – |
2018-08-07 |
4 |
B |
$5.51 |
$55,100 |
D/D |
10,000 |
40,816 |
2.81 |
- |
|
| VNDA |
Vanda Pharmaceuticals Inc... |
Director |
– • – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
10,000 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
